Tapentadol extended release in the management of peripheral diabetic neuropathic pain

References

• MerskeyHBogdukNPart III: pain terms, a current list with definitions and notes on usageClassification of chronic pain, IASP task force on taxonomy2nd edSeattleIASP Press1994209214
   Google Scholar
• HammerslaMKapustinJFPeripheral Neuropathy: Evidence-based treatment of a complex disorderNurse Pract20123753239 quiz 39–4022460540
   PubMedGoogle Scholar
• WigginTDSullivanKAPop-BusuiRAmatoASimaAAFeldmanELElevated triglycerides correlate with progression of diabetic neuropathyDiabetes20095871634164019411614
   PubMed Web of Science ®Google Scholar
• ZhuoMWuGWuLJNeuronal and microglial mechanisms of neuropathic painMol Brain2011431121211057
   PubMedGoogle Scholar
• KressHGTapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?European J Pain201014878178320659810
   PubMed Web of Science ®Google Scholar
• CohenSPMaoJNeuropathic pain: mechanisms and their clinical implicationsBMJ2014348f765624500412
   PubMed Web of Science ®Google Scholar
• WallPDevorMSensory afferent impulses originate from dorsal root ganglia as well as from the periphery in normal and nerve injured ratsPain19831743213396664680
   PubMed Web of Science ®Google Scholar
• BannisterKBeeLADickensonAHPreclinical and early clinical investigations related to monoaminergic pain modulationNeurotherapeutics20096470371219789074
   PubMed Web of Science ®Google Scholar
• AzharyHFarooqMUBhanushaliMMajidAKassabMYPeripheral neuropathy: differential diagnosis and managementAm Fam Phys2010817887892
   PubMed Web of Science ®Google Scholar
• NevilleAPelegRSingerYSherfMShvartzmanPChronic pain: a population-based studyIsr Med Assoc J2008101067668019009944
   PubMed Web of Science ®Google Scholar
• LibermanOPelegRShvartzmanPChronic pain in type 2 diabetic patients: A cross-sectional study in primary care settingEur J Gen Pract201420426026724645789
   PubMed Web of Science ®Google Scholar
• IyerSTanenbergRJPharmacologic management of diabetic peripheral neuropathic painExpert Opin Pharmacother201314131765177523800105
   PubMed Web of Science ®Google Scholar
• HenningsenPZipfelSHerzogWManagement of functional somatic syndromesThe Lancet20073699565946955
   PubMed Web of Science ®Google Scholar
• BansalVKalitaJMisraUDiabetic neuropathyPostgrad Med J2006829649510016461471
   PubMed Web of Science ®Google Scholar
• HjalteFBerggrenA-CBergendahlHHjortsbergCThe direct and indirect costs of opioid-induced constipationJ Pain Symptom Manage201040569670320727708
   PubMed Web of Science ®Google Scholar
• AvouacJGossecLDougadosMEfficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trialsOsteoarthritis Cartilage200715895796517398122
   PubMed Web of Science ®Google Scholar
• EisenbergEMcNicolEDCarrDBEfficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trialsJAMA2005293243043305215972567
   PubMed Web of Science ®Google Scholar
• DworkinRHO’ConnorABBackonjaMPharmacologic management of neuropathic pain: evidence-based recommendationsPain2007132323725117920770
   PubMed Web of Science ®Google Scholar
• KalsoEEdwardsJEMooreRAMcQuayHJOpioids in chronic non-cancer pain: systematic review of efficacy and safetyPain2004112337238015561393
   PubMed Web of Science ®Google Scholar
• Gregorian JrRSGasikAKwongWJVoellerSKavanaghSImportance of side effects in opioid treatment: a trade-off analysis with patients and physiciansJ Pain201011111095110820452835
   PubMed Web of Science ®Google Scholar
• NicholsonBResponsible prescribing of opioids for the management of chronic painDrugs2003631173212487620
   PubMed Web of Science ®Google Scholar
• BenyaminRTrescotAMMDDattaSOpioid complications and side effectsPain Physician2008112 SupplS105S12018443635
   PubMed Web of Science ®Google Scholar
• BellTJPanchalSJMiaskowskiCBolgeSCMilanovaTWilliamsonRThe prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1)Pain Med2009101354218721170
   PubMed Web of Science ®Google Scholar
• PanchalSJMüller-SchwefePWurzelmannJIOpioid-induced bowel dysfunction: prevalence, pathophysiology and burdenInt J Clin Pract20076171181118717488292
   PubMed Web of Science ®Google Scholar
• PappagalloMIncidence, prevalence, and management of opioid bowel dysfunctionAm J Surg20011825A Suppl11S18S11755892
   PubMed Web of Science ®Google Scholar
• ThorpeDMManagement of opioid-induced constipationCurr Pain Headache Rep20015323724011309211
   PubMedGoogle Scholar
• RangHPDaleMMRitterJKMoorePKAnalgesic drugsPharmacology19994587
   Google Scholar
• BagnolDMansourAAkilHWatsonSJCellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tractNeuroscience19978125795919300443
   PubMed Web of Science ®Google Scholar
• McKayJSLinakerBDTurnbergLAInfluence of opiates on ion transport across rabbit ileal mucosaGastroenterology19818022792846256253
   PubMed Web of Science ®Google Scholar
• FickelJBagnolDWatsonSJAkilHOpioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brainBrain Res Mol Brain Res1997461–2189191072
   PubMedGoogle Scholar
• HolzerPOpioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humansNeurosci Lett20043611–319219515135926
   PubMed Web of Science ®Google Scholar
• VevesABackonjaMMalikRAPainful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment optionsPain Med20089666067418828198
   PubMed Web of Science ®Google Scholar
• FinnerupNBOttoMMcQuayHJJensenTSSindrupSHAlgorithm for neuropathic pain treatment: an evidence based proposalPain2005118328930516213659
   PubMed Web of Science ®Google Scholar
• ArgoffCEBackonjaMMBelgradeMJConsensus guidelines: treatment planning and optionsMayo Clinic Proceedings2006814S12S2516608049
   PubMed Web of Science ®Google Scholar
• GimbelJSRichardsPPortenoyRKControlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trialNeurology200360692793412654955
   PubMed Web of Science ®Google Scholar
• WatsonCPMoulinDWatt-WatsonJGordonAEisenhofferJControlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathyPain20031051–2717814499422
   PubMed Web of Science ®Google Scholar
• WatsonCPBabulNEfficacy of oxycodone in neuronathic pain: a randomized trial in postherpetic neuralgiaNeurology1998506183718419633737
   PubMed Web of Science ®Google Scholar
• HaratiYGoochCSwensonMDouble-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathyNeurology1998506184218469633738
   PubMed Web of Science ®Google Scholar
• AttalNCruccuGHaanpääMEFNS guidelines on pharmacological treatment of neuropathic painEur J Neurol200613111153116917038030
   PubMed Web of Science ®Google Scholar
• SchwartzSEtropolskiMShapiroDYSafety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trialCurr Med Res Opin201127115116221162697
   PubMed Web of Science ®Google Scholar
• GrünenthalGmbHGrünenthal GmbH Presents Tapentadol, a Novel Centrally Acting Analgesic, at the 25th Annual Scientific Meeting of The American Pain Society [press release]London, UKPR Newswire2006 Available from: http://www.prnewswire.co.uk/news-releases/grunenthal-gmbh-presents-tapentadol-a-novel-centrally-acting-analgesic-at-the-25th-annual-scientific-meeting-of-the-american-pain-society-153559155.htmlAccessed October 22, 2014
   Google Scholar
• Nucynta (tapentadol) [package insert]Titusville, NJJanssen Pharmaceuticals2009
   Google Scholar
• US Food and Drug AdministrationMedication GuideSilver Spring, MDUS Food and Drug Administration2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200533s000lbl.pdfAccessed October 10, 2014
   Google Scholar
• PalexiaPalexia SR (tapentadol) prolonged-release oral tablets: Summary of product characteristicsBuckinghamshire, UKGrunenthal Ltd2011
   Google Scholar
• CepedaMSSuttonAWeinsteinRKimMEffect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sourcesClin J Pain201228181321646907
   PubMed Web of Science ®Google Scholar
• TzschentkeTDe VryJTerlindenRTapentadol hydrochlorideDrugs Future2006311210531061
   Web of Science ®Google Scholar
• TzschentkeTMChristophTKögelB(−)-(1R, 2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic PropertiesJ Pharmacol Exp Ther2007323126527617656655
   PubMed Web of Science ®Google Scholar
• VarrassiGMarinangeliFPiroliACoaccioliSPaladiniAStrong analgesics: working towards an optimal balance between efficacy and side effectsEur J Pain201014434034220219399
   PubMed Web of Science ®Google Scholar
• WadeWESpruillWJTapentadol hydrochloride: a centrally acting oral analgesicClin Ther200931122804281820110020
   PubMed Web of Science ®Google Scholar
• HartrickCRozekRJTapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitorCNS Drugs201125535937021476608
   PubMed Web of Science ®Google Scholar
• HaleMUpmalisDOkamotoALangeCRauschkolbCTolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind studyCurr Med Res Opin20092551095110419301989
   PubMed Web of Science ®Google Scholar
• CepedaMSFifeDMaQRyanPBComparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort studyJ Pain201314101227124123850177
   PubMed Web of Science ®Google Scholar
• RaffaRBBuschmannHChristophTMechanistic and functional differentiation of tapentadol and tramadolExpert Opin Pharmacother201213101437144922698264
   PubMed Web of Science ®Google Scholar
• CasyAFParfittRTOpioid AnalgesicsNew York, NYPlenum Press1986
   Google Scholar
• MaulCBuschmannHSundermannBSynthetic opioidsBuschmannHChristophTFriderichsEMaulCSunermannBAnalgesics: From Chemistry and Pharmacology to Clinical ApplicationWeinheimWiley-VCH Verlag GmbH & Co. KGaA2002159169
   Google Scholar
• FriderichsEBuschmannHOpioids: 3.4 Opioids with Clinical RelevanceBuschmannHChristophTFriderichsEMaulCSunermannBAnalgesics: From Chemistry and Pharmacology to Clinical ApplicationWiley-VCH Verlag GmbH & Co. KGaA2002171245
   Google Scholar
• GöhlerKBrettMSmitJWRengelshausenJTerlindenRComparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate-and prolonged-release formulationsInt J Clin Pharmacol Ther201351433834823357834
   PubMed Web of Science ®Google Scholar
• AtkinsonTJFudinJPandulaAMirzaMMedication pain management in the elderly: unique and underutilized analgesic treatment optionsClin Ther201335111669168924161287
   PubMed Web of Science ®Google Scholar
• AfilaloMStegmannJUUpmalisDTapentadol immediate release: a new treatment option for acute pain managementJ Pain Res201031921197304
   PubMedGoogle Scholar
• KneipCTerlindenRBeierHChenGInvestigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytesDrug Metab Lett200821677519356073
   PubMedGoogle Scholar
• AfilaloMEtropolskiMSKuperwasserBEfficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo-and active-controlled phase III studyClin Drug Invest2010308489505
   PubMed Web of Science ®Google Scholar
• LernerDChangHRogersWHImputing at-work productivity loss using results of a randomized controlled trial comparing tapentadol extended release and oxycodone controlled release for osteoarthritis painJ Occup Environ Med201254893393822850352
   PubMed Web of Science ®Google Scholar
• PergolizziJAlonEBaronRTapentadol in the management of chronic low back pain: a novel approach to a complex condition?J Pain Res2011420321021887117
   PubMedGoogle Scholar
• SteigerwaldISchenkMLahneUGebuhrPFalkeDHoggartBEffectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis painClin Drug Invest2013339607619
   PubMed Web of Science ®Google Scholar
• DavisRGHepfingerCASauerKAWilhardtMSRetrospective evaluation of medication appropriateness and clinical pharmacist drug therapy recommendations for home-based primary care veteransAm J Geriatr Pharmacother200751404717608246
   PubMedGoogle Scholar
• FudinJOpioid pain management: balancing risks and benefitsDrug Topics201115594658
   Google Scholar
• CoddEEShankRPSchupskyJJRaffaRBSerotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociceptionJ Pharmacol Exp Ther19952743126312707562497
   PubMed Web of Science ®Google Scholar
• MalseedRTGoldsteinFJEnhancement of morphine analgesia by tricyclic antidepressantsNeuropharmacology19791810827829514464
   PubMed Web of Science ®Google Scholar
• BotneyMFieldsHLAmitriptyline potentiates morphine analgesia by a direct action on the central nervous systemAnn Neurol19831321601646219612
   PubMed Web of Science ®Google Scholar
• BuynakRShapiroDYOkamotoAEfficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo-and active-controlled Phase III studyExpert Opin Pharmacother201011111787180420578811
   PubMed Web of Science ®Google Scholar
• LangeBKuperwasserBOkamotoAEfficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back painAdv Ther201027638139920556560
   PubMed Web of Science ®Google Scholar
• MercadanteSPorzioGFerreraPAielliFAdileCFicorellaCLow doses of transdermal fentanyl in opioid-naive patients with cancer painCurr Med Res Opin201026122765276821034376
   PubMed Web of Science ®Google Scholar
• MercadanteSPorzioGFerreraPLow doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational studyClin Ther200931102134213819922884
   PubMed Web of Science ®Google Scholar
• MercadanteSPorzioGFerreraPLow morphine doses in opioid-naive cancer patients with painJ Pain Symptom Manage200631324224716563318
   PubMed Web of Science ®Google Scholar
• MercadanteSPorzioGFerreraPTapentadol in cancer pain management: a prospective open-label studyCurr Med Res Opin201228111775177923057488
   PubMed Web of Science ®Google Scholar
• ImanakaKTominagaYEtropolskiMEfficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related painCurr Med Res Opin201329101399140923937387
   PubMed Web of Science ®Google Scholar
• KressHGKochEKosturskiHTapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related painPain Phys2014174329343
   PubMed Web of Science ®Google Scholar
• BaronRKernUMüllerMDuboisCFalkeDSteigerwaldIEffectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b StudyPain Pract Epub2014418
   Web of Science ®Google Scholar
• ImanakaKTominagaYEtropolskiMOhashiHHiroseKMatsumuraTReady conversion of patients with well-controlled, moderate to severe, chronic malignant tumor–related pain on other opioids to tapentadol extended releaseClin Drug Investig2014347111
   PubMed Web of Science ®Google Scholar
• NiestersMProtoPLAartsLSartonEYDrewesAMDahanATapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathyBri J Anaesth2014aeu056
   Web of Science ®Google Scholar
• VinikAIShapiroDYRauschkolbCA randomized-withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic, painful diabetic peripheral neuropathyDiabetes Care2014DC_132291
   Web of Science ®Google Scholar
• ErlichDRBodineWTapentadol (nucynta) for treatment of painAm Fam Phys2012859910911
   PubMed Web of Science ®Google Scholar
• BiondiDMXiangJEtropolskiMMoskovitzBEvaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysisClinical Drug Investig2014348565576
   PubMed Web of Science ®Google Scholar
• EtropolskiMKuperwasserBFlügelMSafety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trialsAdv Ther201431660462024985410
   PubMed Web of Science ®Google Scholar
• WildJEGrondSKuperwasserBLong-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis painPain Pract201010541642720602712
   PubMed Web of Science ®Google Scholar
• BloorMPaechMKayeRTramadol in pregnancy and lactationInt J Obstet Anesth201221216316722317891
   PubMed Web of Science ®Google Scholar
• TayalGGrewalAMittalRBhatiaNTapentadol: a novel analgesicJ Anaesth Clin Pharmacol2009254463466
   Google Scholar
• ColuzziFRuggeriMClinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal painCurr Med Res Opin20143061139115124528146
   PubMed Web of Science ®Google Scholar
• CroffordLJMeasePJSimpsonSLFibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalinPain2008136341943118400400
   PubMed Web of Science ®Google Scholar
• MooreRAStraubeSDerrySMcQuayHJChronic low back pain analgesic studies–A methodological minefieldPain2010149343143420304558
   PubMed Web of Science ®Google Scholar
• McDermottAMToelleTRRowbothamDJSchaeferCPDukesEMThe burden of neuropathic pain: results from a cross-sectional surveyEur J Pain200610212713516310716
   PubMed Web of Science ®Google Scholar
• TölleTDukesESadoskyAPatient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countriesPain Pract20066315316017147591
   PubMedGoogle Scholar
• GoreMBrandenburgNAHoffmanDLTaiKSStaceyBBurden of illness in painful diabetic peripheral neuropathy: the patients’ perspectivesJ Pain200671289290017157775
   PubMed Web of Science ®Google Scholar
• ArgoffCEThe coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approachClin J Pain2007231152217277640
   PubMed Web of Science ®Google Scholar
• ObradovicMIkenbergRHertelNAntoñanzasFGálvezRLiedgensHCost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTsClin Ther201234492694322417717
   PubMed Web of Science ®Google Scholar